Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diarrhea-Predominant Irritable Bowel Syndrome Clear all
Completed Phase 2 Interventional

A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

NCT01494233
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
250 mg LX1033 tablets, Placebo tablet
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
81
States / cities
Huntsville, Alabama • Tempe, Arizona • Tucson, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Jul 23, 2026, 8:22 AM EDT
Terminated Phase 2 Interventional

Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

NCT01887002
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
ONO-2952, Placebo comparator
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
4
States / cities
Boston, Massachusetts • St Louis, Missouri • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Jul 23, 2026, 8:22 AM EDT
Completed Phase 2 Interventional Results available

Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption

NCT03270085
View directory record Official record
Conditions
Chronic Diarrhea, Irritable Bowel Syndrome With Diarrhea, Bile Acid Malabsorption
Interventions
Colesevelam, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 26, 2020 · Synced Jul 23, 2026, 8:22 AM EDT
Terminated Phase 2 Interventional

Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).

NCT06153420
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
CIN-103, Placebo
Drug
Lead sponsor
CinPhloro Pharma, LLC
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
53
States / cities
Dothan, Alabama • Huntsville, Alabama • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jul 23, 2026, 8:22 AM EDT
Completed Phase 3 Interventional

Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy

NCT00067457
View directory record Official record
Conditions
Irritable Colon, Irritable Bowel Syndrome (IBS)
Interventions
alosetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
190
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Jul 23, 2026, 8:22 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)

NCT01327300
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Mesalamine, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Jul 23, 2026, 8:22 AM EDT
Terminated Phase 1 Interventional

Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome

NCT04655599
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Olorinab, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Jul 23, 2026, 8:22 AM EDT
Completed Phase 2 Interventional Results available

Does Welchol (Colesevelam Hydrochloride) Improve Colonic Transit in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)?

NCT00911612
View directory record Official record
Conditions
Irritable Bowel Syndrome, Diarrhea
Interventions
Colesevelam, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2012 · Synced Jul 23, 2026, 8:22 AM EDT
Completed Phase 4 Interventional

Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea

NCT03729271
View directory record Official record
Conditions
Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea
Interventions
Rifaximin, Glucose and lactulose hydrogen breath testing
Drug · Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jul 23, 2026, 8:22 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

NCT00699166
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
DNK333
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older · Female only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
29
States / cities
Anniston, Alabama • Huntsville, Alabama • Northport, Alabama + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2008 · Synced Jul 23, 2026, 8:22 AM EDT
Completed No phase listed Observational

Retrospective Study of IBS-D Patients Previously Receiving SBI

NCT02661425
View directory record Official record
Conditions
Diarrhoea Predominant Irritable Bowel Syndrome
Interventions
EnteraGam
Other
Lead sponsor
Entera Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Greenwich, Connecticut • Hamdon, Connecticut • Coral Springs, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2016 · Synced Jul 23, 2026, 8:22 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D

NCT02239926
View directory record Official record
Conditions
Diarrhea Predominant Irritable Bowel Syndrome
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Jul 23, 2026, 8:22 AM EDT
Completed Phase 2 Interventional

A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome

NCT00101725
View directory record Official record
Conditions
Irritable Bowel Syndrome, Colonic Diseases, Diarrhea, Gastrointestinal Disease
Interventions
crofelemer
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
29
States / cities
Huntsville, Alabama • Chandler, Arizona • North Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jul 23, 2026, 8:22 AM EDT
Completed Not applicable Interventional

Gluten Intolerance in Patients With Diarrhea Predominant Irritable Bowel Syndrome

NCT01094041
View directory record Official record
Conditions
Diarrhea, Diarrhea Predominant Irritable Bowel Syndrome
Interventions
Gluten free diet, Gluten rich diet
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 9, 2013 · Synced Jul 23, 2026, 8:22 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

NCT02757105
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
BEKINDA, Placebo
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
16
States / cities
Huntsville, Alabama • Little Rock, Arkansas • North Little Rock, Arkansas + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Jul 23, 2026, 8:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mediterranean Diet and the Gut Microbiome

NCT03269032
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
American Diet, Mediterranean-style Diet
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Jul 23, 2026, 8:22 AM EDT
Completed Phase 3 Interventional

Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy

NCT00067561
View directory record Official record
Conditions
Irritable Colon, Irritable Bowel Syndrome (IBS)
Interventions
Alosetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
177
States / cities
Birmingham, Alabama • Calera, Alabama • Tuscaloosa, Alabama + 149 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Jul 23, 2026, 8:22 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

NCT00394173
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea (IBS-D)
Interventions
DNK333, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
180 participants
Timeline
2006 – 2007
U.S. locations
37
States / cities
Tucson, Arizona • North Little Rock, Arkansas • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Jul 23, 2026, 8:22 AM EDT
Completed Not applicable Interventional Results available

Effects of a Very Low Carbohydrate Diet on Symptoms of Irritable Bowel Syndrome (IBS)

NCT00616200
View directory record Official record
Conditions
Diarrhea Predominant Irritable Bowel Syndrome
Interventions
Very low carbohydrate diet
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2017 · Synced Jul 23, 2026, 8:22 AM EDT
Completed Phase 2 Interventional

A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

NCT01896583
View directory record Official record
Conditions
Diarrhea Predominant Irritable Bowel Syndrome
Interventions
ASP7147, Placebo
Drug
Lead sponsor
Seldar Pharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Phoenix, Arizona • Encino, California • La Mesa, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Jul 23, 2026, 8:22 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

NCT03977155
View directory record Official record
Conditions
Diarrhea-predominant Irritable Bowel Syndrome
Interventions
BOS-589, Placebo
Drug
Lead sponsor
Boston Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
58
States / cities
Anniston, Alabama • Huntsville, Alabama • Chandler, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Jul 23, 2026, 8:22 AM EDT
Completed Phase 2 Interventional

A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

NCT01844180
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
ONO-2952, ONO-2952 Matching Placebo
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
48
States / cities
Anniston, Alabama • Goodyear, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Jul 23, 2026, 8:22 AM EDT
Completed Not applicable Interventional

Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth

NCT02251483
View directory record Official record
Conditions
Diarrhea Predominant Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Interventions
Serum-derived bovine immunoglobulin protein isolate (SBI), Placebo
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2015 · Synced Jul 23, 2026, 8:22 AM EDT
Terminated Not applicable Interventional

Effect of Acupuncture on Symptoms of Diarrhea and Pain in IBS

NCT00219505
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
acupuncture
Procedure
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Jul 23, 2026, 8:22 AM EDT